Tryptamine Therapeutics ( (AU:TYP) ) has issued an announcement.
Tryptamine Therapeutics announced that all resolutions were passed at their General Meeting, signaling shareholder support for the company’s strategic direction. The company has completed successful Phase 2a clinical trials for binge eating disorder and fibromyalgia, with ongoing trials for irritable bowel syndrome, positioning it as a leader in the development of psilocin-based therapies.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing proprietary formulations of psilocin for use in psychotherapy to treat diseases with unmet medical needs. Their lead asset, TRP-8803, is an innovative IV-infused psilocin formulation aimed at improving the efficacy and safety of treatments for conditions like binge eating disorder and fibromyalgia.
YTD Price Performance: -10.53%
Average Trading Volume: 1,643,646
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$48.92M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.